iShares Biotechnology ETF
584 hedge funds and large institutions have $6.45B invested in iShares Biotechnology ETF in 2017 Q3 according to their latest regulatory filings, with 78 funds opening new positions, 212 increasing their positions, 173 reducing their positions, and 52 closing their positions.
50% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 52
23% more repeat investments, than reductions
Existing positions increased: 212 | Existing positions reduced: 173
18% more capital invested
Capital invested by funds: $5.46B → $6.45B (+$989M)
17.09% more ownership
Funds ownership: 169.44% → 186.53% (+17%)
4% more funds holding
Funds holding: 562 → 584 (+22)
9% less funds holding in top 10
Funds holding in top 10: 33 → 30 (-3)
22% less call options, than puts
Call options by funds: $815M | Put options by funds: $1.05B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$929M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$130M |
| 3 |
N
Natixis
Paris,
France
|
+$95.2M |
| 4 |
Goldman Sachs
New York
|
+$87.3M |
| 5 |
Jane Street
New York
|
+$51.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$270M |
| 2 |
Morgan Stanley
New York
|
-$100M |
| 3 |
SIG
Senator Investment Group
New York
|
-$93M |
| 4 |
AL
Appaloosa LP
Short Hills,
New Jersey
|
-$72.9M |
| 5 |
QIM
Quantitative Investment Management
Charlottesville,
Virginia
|
-$68.8M |
IBB Hedge Fund Activity: Q3 2017 in Review
584 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q3 2017, worth a combined $6.45B — up 18% from $5.46B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new IBB positions and 52 closed out — a net gain of 26 holders — while 212 added to existing stakes and 173 trimmed.
The largest buyer was Bank of America, adding an estimated $929M. The largest seller was Citigroup, cutting an estimated $270M.
- 584 institutional investors held iShares Biotechnology ETF (IBB) as of Q3 2017, up from 562 in Q2 2017.
- Funds reported $6.45B of iShares Biotechnology ETF stock for Q3 2017, up 18% quarter-over-quarter.
- 78 funds opened new iShares Biotechnology ETF positions in Q3 2017 and 52 closed out, a net change of +26 holders.
- The largest iShares Biotechnology ETF buyer in Q3 2017 was Bank of America, an estimated $929M added.
- The largest iShares Biotechnology ETF seller in Q3 2017 was Citigroup, an estimated $270M sold.
Based on aggregated 13F filings for Q3 2017.